Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Operating Leases: 2020-2025

Historic Operating Leases for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $5.3 million.

  • Arcutis Biotherapeutics' Operating Leases rose 90.33% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 90.33%. This contributed to the annual value of $2.6 million for FY2024, which is 24.25% down from last year.
  • Arcutis Biotherapeutics' Operating Leases amounted to $5.3 million in Q3 2025, which was up 149.57% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Operating Leases peaked at $5.3 million during Q3 2025, and registered a low of $2.1 million during Q2 2025.
  • Its 3-year average for Operating Leases is $3.5 million, with a median of $3.2 million in 2024.
  • In the last 5 years, Arcutis Biotherapeutics' Operating Leases surged by 1,812.88% in 2021 and then plummeted by 35.31% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' Operating Leases (Quarterly) stood at $4.8 million in 2021, then declined by 13.76% to $4.1 million in 2022, then declined by 17.85% to $3.4 million in 2023, then declined by 24.25% to $2.6 million in 2024, then surged by 90.33% to $5.3 million in 2025.
  • Its Operating Leases stands at $5.3 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.3 million for Q1 2025.